Exploring public and community engagement with vaccine research across four broad themes

Created following a Mesh workshop exploring public and community engagement with vaccine studies held in autumn 2020. Each of the four workshop sessions had a loose overarching theme chosen to enable participants to unpack some of the complex issues surrounding engaging communities with vaccine research and development. Under each theme below we share projects, thoughts from participants and ways of supporting impactful engagement activities.

View the content

 

EDCTP Knowledge Hub

The mission of the European & Developing Countries Clinical Trials Partnership (EDCTP) is to contribute to the reduction of the individual, social and economic burden of poverty-related infectious diseases in sub-Saharan Africa.

As a major funder of clinical trials and clinical studies, the EDCTP supports collaborative research that accelerates the development of accessible, suitable and affordable medical interventions (drugs, vaccines, microbicides and diagnostics) to identify, prevent or treat HIV, tuberculosis (TB), malaria and neglected infectious diseases in the region.

The New Vaccine

Here, you'll find a comprehensive resource dedicated to the latest advancements and information surrounding the development of the malaria vaccine.

First malaria vaccine supply allocations (May 2023): Explanation of process and outcomes

This document outlines the procedure and underlying reasons behind the distribution of the initial 18 million malaria vaccine doses, which are presently earmarked for allocation between 2023 and 2025 to countries endorsed for assistance by Gavi, the Vaccine Alliance. The distribution process adheres to the Framework for Allocating Limited Malaria Vaccine Supply, established by the World Health Organization (WHO) in 2022.

Malaria vaccine market shaping roadmap (GAVI White Paper on Malaria)

This document provides a concise narrative of Gavi's collaborative efforts with various stakeholders to increase malaria vaccine supply to meet demand by 2026, diversify vaccine suppliers, understand vaccine demand dynamics, and foster innovation in the malaria vaccine field.

Malaria Vaccine: Questions and Answers on Vaccine Supply, Price, and Market Shaping July 2023

This document offers a comprehensive overview of malaria vaccine supply, pricing, and the ongoing initiatives to shape the market. It serves as a valuable supplement to publicly available information regarding programmatic aspects and Gavi application criteria. The content encompasses the preliminary results arising from UNICEF's malaria vaccine tender, derived through a thorough assessment of submitted proposals, extensive negotiations, and ongoing consultations with our partners.

Framework for the allocation of limited malaria vaccine supply

The Framework provides essential guidance for the worldwide allocation of RTS,S/AS01 and other forthcoming malaria vaccines among countries. It outlines recommendations for prioritizing vaccination within countries until supply limitations are adequately addressed.

Efficacy and immunogenicity of R21/Matrix-M vaccine against clinical malaria after 2 years' follow-up in children in Burkina Faso: a phase 1/2b randomised controlled trial

This study reports the findings of a phase 1/2b randomized controlled trial conducted in Burkina Faso. The trial aimed to assess the effectiveness and immune response of the R21/Matrix-M malaria vaccine over a two-year follow-up period in children.

Estimated impact of RTS,S/AS01 malaria vaccine allocation strategies in sub-Saharan Africa: A modelling study

This study utilized modeling to estimate the potential effects of different allocation strategies for the RTS,S/AS01 malaria vaccine in sub-Saharan Africa. The results indicate that by introducing the vaccine at a sub-national level and giving priority to countries with the highest malaria incidence, it may be possible to mitigate the impact of vaccine supply constraints on the public health outcomes associated with the RTS,S malaria vaccine.

Seasonal Malaria Vaccination with or without Seasonal Malaria Chemoprevention

This study revealed that the administration of RTS,S/AS01E (a malaria vaccine) was found to be as effective as chemoprevention in preventing uncomplicated malaria. However, when both interventions were combined, there was a significant reduction in the incidence of uncomplicated malaria, severe malaria, and malaria-related deaths compared to using either intervention alone.

Efficacy and safety of RTS,S/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trial

This study presents the conclusive findings of a phase 3 clinical trial. In this trial, individuals, including infants and children in Africa, were individually randomized to receive the RTS,S/AS01 malaria vaccine either with or without a booster dose. The study assessed the efficacy and safety of the vaccine under these conditions and provides the final results of the trial.

Public health impact and cost-eff ectiveness of the RTS,S/AS01 malaria vaccine: a systematic comparison of predictions from four mathematical models

This article presents a comprehensive evaluation of the potential public health impact and cost-effectiveness of the RTS,S/AS01 malaria vaccine. This assessment is based on predictions generated by four distinct mathematical models. The study systematically compares these predictions to provide a comprehensive understanding of the vaccine's potential benefits and cost-effectiveness in the context of malaria control and prevention.

Full Evidence Report on the RTS,S/AS01 Malaria Vaccine (WHO Background Paper)

This document offers a comprehensive analysis of the vaccine's safety, impact, and feasibility. It includes in-depth information derived from clinical trials and research, providing valuable insights into the vaccine's effectiveness in combating malaria.

Malaria vaccine: WHO position paper – March 2022

This position paper represents the latest guidance from the World Health Organization (WHO) and replaces the previous 2016 publication, "Malaria vaccine: WHO position paper-2016." It includes updated WHO recommendations regarding the broader application of the RTS,S/AS01 vaccine, aimed at reducing malaria-related illness and death in children residing in regions with moderate to high malaria transmission.

Update on the RTS,S/AS01 Malaria Vaccine Implementation Programme

This document provides the latest information regarding the deployment and utilization of the RTS,S/AS01 malaria vaccine. The update typically includes details on progress, coverage rates, challenges, and any adjustments made to the implementation strategy.

Malaria Vaccines: Recent Advances and New Horizons

This article discusses the ongoing efforts to develop highly effective and long-lasting vaccines against the human malaria parasites Plasmodium falciparum and P. vivax. It highlights the first-generation pre-erythrocytic vaccines that are nearing licensure in the coming years and emphasizes the importance of exploring next-generation approaches to build upon their success.

Malaria vaccine wows and seeds COVID-19 vaccine effort

The article suggests that the success and advancements in the development of a malaria vaccine have not only been promising for addressing malaria but have also had a positive impact on the efforts to develop COVID-19 vaccines.

A qualitative assessment of the challenges of WHO prequalification for anti-malarial drugs in China

This study examines and evaluates the obstacles faced by China in obtaining WHO prequalification for its anti-malarial drugs. This qualitative assessment explores the various issues, regulatory hurdles, and quality assurance challenges that China encounters in its efforts to meet WHO standards for malaria treatment drugs.